NCT01646840

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

a Phase 1, Open-Label, Single Dose, Relative Bioavailability Study In Healthy Volunteers Comparing PF-04958242 Capsule Formulation To PF-04958242 Oral Solution In The Fasted State

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Biogen · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will assess the relative bioavailability of a capsule formulation of PF-04958242, relative to a oral solution formulation of PF-04958242 in healthy adult subjects.

Detailed description

This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	PF-04958242 capsule	Single dose of PF-04958242 0.35 mg oral capsule
DRUG	PF-04958242 oral solution	Single dose of PF-04958242 0.35 mg oral solution

Timeline

• Start date: 2012-07-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2012-07-20
• Last updated: 2019-11-21

Locations

1 site across 1 country: United States